Thorne HealthTech, Inc.

NasdaqGS:THRN 株式レポート

時価総額：US$550.6m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Thorne HealthTech マネジメント

マネジメント 基準チェック /34

現在、CEO に関する十分な情報がありません。

主要情報

Paul Jacobson

最高経営責任者

US$4.1m

報酬総額

CEO給与比率12.96%
CEO在任期間13.8yrs
CEOの所有権n/a
経営陣の平均在職期間9.8yrs
取締役会の平均在任期間8.4yrs

経営陣の近況

Recent updates

分析記事 • Aug 12

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Thorne HealthTech, Inc. ( NASDAQ:THRN ) defied analyst predictions to release its second-quarter results, which were...
分析記事 • Jun 07

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

With a price-to-earnings (or "P/E") ratio of 25.5x Thorne HealthTech, Inc. ( NASDAQ:THRN ) may be sending very bearish...
分析記事 • Dec 17

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'd want to...
Seeking Alpha • Sep 09

Thorne HealthTech Grows But Faces Macro Headwinds

Summary Thorne HealthTech went public in September 2021, raising approximately $70 million in a U.S. IPO. The company designs and sells wellness and nutraceutical products worldwide. THRN has produced revenue growth but faces inflationary pressures, the loss of a significant distributor in Europe and the stock may be fully valued here. I'm on Hold for THRN for the near term. A Quick Take On Thorne HealthTech Thorne HealthTech, Inc. (THRN) went public in September 2021, raising approximately $70 million in gross proceeds from an IPO that priced at $10.00 per share. The firm designs and sells wellness and nutraceutical products under its brands Thorne and Onegevity. Given the risks of continued inflationary pressures and a macroeconomic slowdown combined with a potentially fully valued stock at its current price of around $5.00 per share, I'm on Hold for THRN in the near term. Thorne HealthTech Overview New York, NY-based Thorne was founded to develop premium wellness products for consumers utilizing its Onegevity platform to discover and develop new products. The firm sells products directly and also has a product subscription program Management is headed by Chief Executive Officer Paul Jacobson, who has been with the firm since 2010 when he acquired Thorne Research and was previously co-founder of Onegevity Health, which was acquired by Thorne. THRN sells its products through a direct to consumer channel [DTC] as well as through online ecommerce sites such as Amazon, distributors and through connected health professionals. The company also gathers personalized testing data and has plans to use this information for additional services to practitioners. Thorne HealthTech's Market & Competition According to a 2021 market research report by Grand View Research, the global market for dietary supplements was an estimated $140.3 billion in 2020 and is forecast to reach $271 billion by 2028. This represents a forecast CAGR of 8.6% from 2021 to 2028. The main drivers for this expected growth are a growing consumer awareness of personal health and wellness products as well as increased R&D from product makers. Also, below is a chart showing the historical and projected future market size by ingredient for dietary supplements in the U.S.: U.S. Dietary Supplements Market (Grand View Research) Major competitive or other industry participants include: Nestle Health Science Metagenics Hims 23and Me Livongo Schrodinger SEMA4 Numerous other nutritional supplement companies Thorne HealthTech's Recent Financial Performance Total revenue by quarter has grown according to the following chart: 9 Quarter Total Revenue (Seeking Alpha) Gross profit by quarter has followed approximately the same trajectory as that of total revenue: 9 Quarter Gross Profit (Seeking Alpha) Selling, G&A expenses as a percentage of total revenue by quarter rose substantially in the most recent quarter: 9 Quarter Selling, G&A % Of Revenue (Seeking Alpha) Operating income by quarter has turned negative in Q2 2022: 9 Quarter Operating Income (Seeking Alpha) Earnings per share (Diluted) have turned into negative territory in Q2 2022: 9 Quarter Earnings Per Share (Seeking Alpha) (All data in above charts is GAAP) Since its IPO, THRN's stock price has fallen 38.4% vs. the U.S. S&P 500 index' drop of around 9.9%, as the chart below indicates: Stock Price Since IPO (Seeking Alpha) Valuation And Other Metrics For Thorne HealthTech Below is a table of relevant capitalization and valuation figures for the company: Measure [TTM] Amount Enterprise Value / Sales 1.31 Revenue Growth Rate 28.5% Net Income Margin 0.97 GAAP EBITDA % 1.8% Market Capitalization $267,930,000 Enterprise Value $272,780,000 Operating Cash Flow $1,190,000 Earnings Per Share (Fully Diluted) $0.04 (Source - Seeking Alpha) Below is an estimated DCF (Discounted Cash Flow) analysis of the firm's projected growth and earnings: Discounted Cash Flow - Thorne (GuruFocus) Assuming generous DCF parameters, the firm's shares would be valued at approximately $5.13 versus the current price of $5.01, indicating they are potentially currently fully valued, with the given earnings, growth and discount rate assumptions of the DCF. As a reference, a relevant partial public comparable would be larger firm Glanbia plc (GLAPF, GLAPY); shown below is a comparison of their primary valuation metrics: Metric Glanbia plc Thorne HealthTech Variance Enterprise Value / Sales 0.79 1.31 65.8% Revenue Growth Rate 23.7% 28.5% 20.3% Net Income Margin 5.4% 0.97 1689.7% Operating Cash Flow $104,990,000 $1,190,000 -98.9% (Source - Seeking Alpha) A full comparison of the two companies' performance metrics may be viewed here. Commentary On Thorne HealthTech In its last earnings call (Source - Seeking Alpha), covering Q2 2022's results, management highlighted improvements in its sales mix and the effect of increased prices and scale growth as offsets to inflationary pressures on its cost of sales. Notably, the firm's Pro and B2B sales channels produced strong growth year-over-year, excluding the loss of a distributor related to the conflict in Ukraine, which it estimates reduced Q2 revenue by "as much as $6.9 million."
Seeking Alpha • Aug 23

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Thorne HealthTech (NASDAQ:THRN) said its blood collection device OneDraw was certified in Japan as a medical device after being cleared by the Pharmaceutical and Medical Devices Agency (PMDA). "We appreciate the help from our partners in Japan because we believe this will create many additional opportunities to expand our relationships globally, while we continue to move forward on a similar regulatory pathway in the United States," said Thorne CEO Paul Jacobson. The company noted that OneDraw is already approved by the FDA as a class 2 medical device, and it has a European Conformity mark for supervised use by health-care professionals to collect blood samples to measure HbA1c for monitoring the long-term control of blood sugar (glucose) in diabetic individuals.
Seeking Alpha • Aug 09

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Thorne HealthTech press release (NASDAQ:THRN): Q2 Non-GAAP EPS of -$0.05 (vs. $0.22 Y/Y). Revenue of $56.1M (+30.8% Y/Y). FY22 guidance revised to net sales of $235M to $242M (vs. consensus of $247.13M) and EPS of of $0.36 to $0.39 (vs. consensus of $0.34). Shares -1.47% AH.
Seeking Alpha • Jun 05

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Nutraceutical companies will perform well during the next decade, even during a recession. DIY health trends are on the rise. Thorne HealthTech is well-positioned to benefit from these trends.
分析記事 • Mar 23

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Thorne HealthTech, Inc.'s ( NASDAQ:THRN ) strong earnings report was rewarded with a positive stock price move. We have...
Seeking Alpha • Jan 11

Thorne HealthTech: Good Potential At A Low Price

The market oversold Thorne shares. The company is growing at double-digit rates. It has strong positioning and enormous market potential. If marketing efficiency remains the same in the coming years, revenue will grow exponentially. This scenario is highly likely because the indicator is increasing. Despite the stage of aggressive growth, Thorne is already a profitable company. We expect the company to continue growing and improve profitability. The company is trading at a significant discount to its fair market value. PEG ratio is less than 1.

CEO報酬分析

Thorne HealthTech の収益と比較して、Paul Jacobson の報酬はどのように変化したか？
日付総報酬給与会社業績
Jun 30 2023n/an/a

US$20m

Mar 31 2023n/an/a

US$10m

Dec 31 2022US$4mUS$530k

US$16m

Sep 30 2022n/an/a

US$6m

Jun 30 2022n/an/a

US$3m

Mar 31 2022n/an/a

US$9m

Dec 31 2021US$13mUS$530k

US$4m

Sep 30 2021n/an/a

-US$822k

Jun 30 2021n/an/a

-US$1m

Mar 31 2021n/an/a

-US$3m

Dec 31 2020US$759kUS$530k

-US$3m

報酬と市場: Paulの 総報酬 ($USD 4.09M ) は、 US市場 ($USD 2.48M ) の同規模の企業の平均を上回っています。

報酬と収益: Paulの報酬は、過去 1 年間の会社の業績と一致しています。

CEO

Paul Jacobson (68 yo)

13.8yrs
在職期間
US$4,088,000
報酬

Mr. Paul F. Jacobson Co-Founded Thorne HealthTech, Inc. in 2010 and has been its Chief Executive Officer and Director since 2010. He is Chairman of Thorne HealthTech, Inc. He was Interim Principal Financi...

リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Paul Jacobson
Co-Founder13.8yrsUS$4.09mデータなし
William McCamy
Presidentno dataUS$1.35mデータなし
Saloni Varma
CFO & Directorless than a yearUS$463.20k0.032%
$ 173.4k
Thomas McKenna
COO & Director13.8yrsUS$2.89mデータなし
Scott Hurth
Chief Technology Officer9.8yrsデータなしデータなし
Nathan Price
Chief Scientific Officer & CEO of Onegevityno dataデータなしデータなし
Thomas Wilson
VP & Head of Investor Relationsno dataデータなしデータなし
Kim Pearson
General Counsel28.8yrsデータなしデータなし
Michelle Crow
Chief Marketing Officer5.9yrsデータなしデータなし
Rob Monteleone
Senior VP of Professional Salesno dataデータなしデータなし
Bodi Zhang
Chief Strategy Officerno dataデータなしデータなし
Stephen Phipps
Chief Innovation Officer2.8yrsデータなしデータなし
9.8yrs
平均在職期間
45.5yo
平均年齢

経験豊富な経営陣: THRNの経営陣は経験豊富で経験豊富です（平均在職期間は9.8年）。

取締役

名称ポジション在職期間報酬所有権
Paul Jacobson
Co-Founder13.8yrsUS$4.09mデータなし
Saloni Varma
CFO & Director2.1yrsUS$463.20k0.032%
$ 173.4k
Thomas McKenna
COO & Director13.8yrsUS$2.89mデータなし
Riccardo Braglia
Independent Director11.8yrsデータなし0%
$ 0
Sarah Kauss
Independent Director2.1yrsUS$469.45k0.021%
$ 114.6k
Toshitaka Inuzuka
Independent Director5yrsデータなし0%
$ 0
8.4yrs
平均在職期間
58.5yo
平均年齢

経験豊富なボード: THRNの 取締役会 は 経験豊富 であると考えられます ( 8.4年の平均在任期間)。

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2023/10/18 05:29
終値2023/10/13 00:00
収益2023/06/30
年間収益2022/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Thorne HealthTech, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5

アナリスト機関
Bryan SpillaneBofA Global Research
Susan AndersonCanaccord Genuity
Elizabeth AndersonEvercore ISI